CDK9 inhibitors in cancer research

doi:10.1039/d2md00040g

	CDK9 inhibitors in cancer research
	Huang, Zhi 1,2; Wang, Tianqi 2; Wang, Cheng 2; Fan, Yan 2
刊名	RSC MEDICINAL CHEMISTRY
	2022-04-20
DOI	10.1039/d2md00040g
通讯作者	Fan, Yan(yanfan@nankai.edu.cn)
英文摘要	Cyclin dependent kinase 9 (CDK9) plays an essential role in regulating transcriptional elongation. Aberrations in CDK9 activity have been observed in various cancers, which make CDK9 an attractive therapeutic target for cancers. This led to an intensive development of small-molecule CDK9 inhibitors or new emerging strategies, such as proteolysis targeting chimeras (PROTACs). Here, we review the CDK9 modulators in cancer not only for research purposes, but also for therapeutic applications.
资助项目	National Natural Science Foundation of China[81903099]
WOS关键词	CYCLIN-DEPENDENT KINASE ; POTENT ANTITUMOR-ACTIVITY ; SINGLE-AGENT ACTIVITY ; CYC202 R-ROSCOVITINE ; IN-VITRO ; CELL-CYCLE ; SELICICLIB CYC202 ; MULTIPLE-MYELOMA ; DOWN-REGULATION ; TARGETING CDK9
WOS研究方向	Biochemistry & Molecular Biology ; Pharmacology & Pharmacy
语种	英语
出版者	ROYAL SOC CHEMISTRY
WOS记录号	WOS:000795942000001
资助机构	National Natural Science Foundation of China
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/130959]
专题	中国科学院合肥物质科学研究院
通讯作者	Fan, Yan
作者单位	1.Chinese Acad Sci, Inst Hlth & Med Technol, Hefei Inst Phys Sci, Anhui Prov Key Lab Med Phys & Technol, Hefei 230031, Peoples R China 2.Nankai Univ, Sch Med, Dept Med Chem, 94 Weijin Rd, Tianjin 300071, Peoples R China
推荐引用方式 GB/T 7714	Huang, Zhi,Wang, Tianqi,Wang, Cheng,et al. CDK9 inhibitors in cancer research[J]. RSC MEDICINAL CHEMISTRY,2022.
APA	Huang, Zhi,Wang, Tianqi,Wang, Cheng,&Fan, Yan.(2022).CDK9 inhibitors in cancer research.RSC MEDICINAL CHEMISTRY.
MLA	Huang, Zhi,et al."CDK9 inhibitors in cancer research".RSC MEDICINAL CHEMISTRY (2022).